Background: RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western European countries. This creates problems in clinical situations that require urgent treatment and for inclusion in therapeutic trials that need RAS status for randomization. Analysis of circulating tumor DNA might help to shorten the time required to determine RAS mutational status before anti-epidermal growth factor receptor antibody therapy for metastatic colorectal cancer. Here we compared plasma with tissue RAS analysis in a large prospective multicenter cohort.
Introduction
RAS molecular testing has become a key element in the management of patients with colorectal cancer [1] and is currently determined by analyzing tumor samples. This requires a complex network of clinicians, pathologists and molecular biologists, who may not be located in the same health care structure. Surveys conducted in western European countries suggest that it takes about 3 weeks to obtain RAS mutation status [2, 3] , potentially hindering timely first-line treatment. As first-line combination therapy with anti-epidermal growth factor receptor antibody has been reported to improve response rates and survival, a significant group of patients lacking their RAS results may not receive optimal first-line chemotherapy, with negative consequences for tumor symptoms, secondary resection and survival [1, 4] . Clinical trials focusing on RAS wild-type metastatic colorectal cancer are also hindered by the time required to obtain RAS status.
Molecular analysis of circulating tumor DNA (ctDNA) shed into the circulation by dying tumor cells might hasten RAS mutation detection and also reduce costs. Various methods have been developed to detect specific molecular alterations and for wholegenome analysis [5] [6] [7] [8] . ctDNA testing is highly specific but its sensitivity is influenced by technical issues and by tumor characteristics, especially tumor stage [6, 8] . ctDNA has already been used to analyze EGFR mutational status in non-small-cell lung cancer [9] . In this latter setting, EGFR mutations are associated with therapeutic efficacy of EGFR tyrosine kinase inhibitors, and a low sensitivity only reduces the number of eligible patients. In contrast, RAS mutations are associated with a potential detrimental effect of anti-EGFR antibodies in patients with metastatic colorectal cancer [1] . Thus, before using ctDNA routinely to assess RAS mutation status, it is necessary to demonstrate strong concordance between plasma and tissue analysis and a highly sensitive method is necessary to avoid false-negative results.
In this prospective multicenter study, we investigated the concordance of RAS status between paired plasma and tumor samples from chemotherapy-naive patients with metastatic colorectal cancer.
Methods

Study design and participants
Patients were eligible for the study if they were 18 years or older and had pathologically confirmed metastatic colorectal cancer not previously treated with chemotherapy (with the exception of adjuvant chemotherapy completed !6 months before enrollment). The exclusion criteria were as follows: no available tumor block, another malignancy in the past 5 years, and medical, sociological, psychological or legal conditions that would not permit the patient to provide informed consent.
The Ile-de-France IV ethics committee approved the research protocol, and all the patients gave their written informed consent. The trial conformed to the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Conference on Harmonization, and relevant French and European laws and directives. The protocol was registered with Clinicaltrials.gov (No: NCT02502656).
Procedures
Anonymized blood samples were collected before any anticancer treatment, in three 10-ml Streck V R tubes. Upon receipt by the centralized laboratory, the tubes were centrifuged 10 minutes at 1600 g, the plasma was recovered and a second centrifugation was carried out for 10 minutes at 6000 g. The plasma was then transferred in LoBind tubes (Eppendorf) and stored at À80 C until ctDNA analysis.
In parallel, tumor RAS status was determined by a French National Cancer Institute (INCa)-approved molecular oncology laboratory and was used to guide patient care according to standard recommendations. Anonymized tumor RAS status reports were centralized. The choice of first-line chemotherapy was left to the investigators, who were blinded to the results of plasma RAS analysis.
Data collection
Clinical and biological data at inclusion as well as information about the 'standard' RAS assessment were collected in an electronic case report form based on Cleanweb software (V C 2017 Telemedicine Technologies, France; see supplementary appendix, available at Annals of Oncology online).
RAS assessment in circulating tumor DNA
Complete information on the methodology used are detailed in the supplementary appendix, available at Annals of Oncology online. Briefly, circulating cell-free DNA was sequenced using the AmpliSeq Colon and Lung Cancer Panel V2 on an Ion Proton following the manufacturer's recommendations (Life Technologies V R ), and date were analyzed using the BPER method [10] . The BPER method is a method based on quantification of error rate of each base position (PER). It allows to identify mutations using a binomial test comparing the minor-allele frequency to the measured PER at each position. With this methodology, we were able to detect minimal mutated allele frequencies of 0.003 for single-nucleotide variations and 0.001 for insertions/deletions with a strong agreement with droplet digital PCR (ddPCR) (score j ¼ 0.90) [10] .
When no mutation was identified by targeted next-generation sequencing (NGS), we used two methylated colorectal cancer-specific biomarkers (WIF1 and NPY) by ddPCR to determine the presence or absence of ctDNA in plasma (Figure 1 ) [11] .
Centrally analyzed tumor samples
When RAS mutations were detected in ctDNA but not in the corresponding tumor sample, available remaining tumor samples were analyzed centrally after a second DNA extraction, using the same NGS panel as for plasma. Tumor DNAs were analyzed using the Iontorrent Suite software. Annotation of VCF files from the Variant caller plugin was done on a galaxy platform that generates an annotate data file using the pipeline developed for SAFIR trials (Safir2.4 report tool version 2.4). accuracy and expected accuracy (random chance). For example, a j value of 0.7 means that agreement is 70% better than by chance alone.
The sample size was determined to assess the concordance measured by the j coefficient regarding RAS mutation result (yes versus no) between the ctDNA and tumor results (considering tumor RAS status as the reference). We postulated a 55% frequency of mutated RAS and a j coefficient of 0.7 (considered satisfactory in Cohen's classification). With these hypotheses, and in order to achieve a precision of 60.07 [95% confidence interval (CI), 0.63-0.77] for the j coefficient, 405 patients were required. With an expected 5% rate of loss to follow-up and/or unassessable/unavailable specimens, a total of 425 patients had to be enrolled.
All analyses used SAS software version 9.4 (SAS Institute, Cary, NC). P values <0.05 were considered statistically significant, and all tests were two sided.
Additional information concerning statistical analyses are given in the supplementary appendix, available at Annals of Oncology online.
Results
Patient characteristics
Between July 2015 and December 2016, 425 patients were enrolled in 14 French centers, of whom 13 (3%) did not meet the inclusion criteria owing to a lack of tumor tissue or plasma (CONSORT diagram, supplementary Figure S1 , available at Annals of Oncology online). The characteristics of the 412 patients included in the concordance analyses are described in the supplementary Table S2 , available at Annals of Oncology online.
RAS mutation status
RAS mutations were detected in 237 (58%) of the 412 tumor samples. Preanalytical data, general methodologies used by the INCa-approved laboratories and the time required to obtain the results are described in supplementary Tables S3 and S4, available at Annals of Oncology online. Eight (2%) of the 412 patients had RAS mutations in plasma but not in the locally analyzed tumor sample. Remnant tumor samples from six of these eight patients were then analyzed centrally, revealing RAS mutations in five cases using NGS analysis. The last case was analyzed by ddPCR dedicated RAS assay and revealed a mutant allele frequency of 0.98%. The overall prevalence of RAS mutations in tumor tissue was thus 59% (242 of 412 samples) (Figure 1) .
RAS mutations were detected in plasma from 187 (45%) of the 412 patients: 171 patients (42%) had KRAS mutations, 15 patients (4%) had NRAS mutations, and 1 patient had both KRAS and NRAS mutations. Among the remaining 225 patients, 112 patients (27%, 112/412) with no RAS mutations had a mutation in one of the other 20 sequenced genes, thus confirming the presence of ctDNA. In the remaining 113 patients (27%, 113/412) in whom no mutations were detected with the NGS panel, 30 patients (7%) were positive for either WIF1 or NPY and were thus ctDNA-positive, while the remaining 83 patients (20%) were negative. Altogether, 329 patients (80%) had conclusive ctDNA results, while the remaining 83 patients had inconclusive ctDNA results (Figure 1 ).
Concordance between plasma and tumor RAS status
In the group of 412 patients tested for RAS mutations in both plasma and tissue, the j coefficient was 0.71 (95% CI, 0.64-0.77), the accuracy was 85.2% (95% CI, 81.4-88.5), the sensitivity 76.0% (95% CI, 70.2-81.3) and the specificity 98.2% (95% CI, 94.9-99.6). In the 329 patients with detectable ctDNA, the j coefficient was 0.89 (95% CI, 0.84-0.94), the accuracy was 94.8% (95% CI, 91.9-97.0), the sensitivity 92.9% (95% CI, 88.4-96.1) and the specificity 97.7% (95% CI, 93.5-99.5) (supplementary Table S5 , available at Annals of Oncology online).
Patients with inconclusive ctDNA results
Primary tumor resection, metachronous metastases, the absence of liver metastases, and peritoneal carcinomatosis were significantly more frequent among the 83 patients with inconclusive ctDNA results. These patients had lower leukocyte counts, lower LDH, alkaline phosphatase, Ca 19-9 and CEA levels, and higher albumin levels ( Tables S6 and S7 , available at Annals of Oncology online). The j coefficients and accuracies are shown in Table 2 according to these parameters.
Discordant cases in patients with conclusive ctDNA results
Three patients (<1%) had RAS plasma mutations but no RAS tumor mutations, while 14 patients (4%) had RAS tumor mutations but no RAS plasma mutations. No methodological differences were observed between concordant and discordant cases. By comparison with patients with concordant RAS mutation status, patients in the latter group were significantly more likely to have metachronous metastases and peritoneal carcinomatosis and significantly less likely to have liver metastases (supplementary Table S8 , available at Annals of Oncology online). These 14 patients have been classified as non-RAS mutated in their plasma based on the presence of other gene mutation than RAS in 12 patients and/or on a positive methylation assay in 9 patients. The allelic frequency of these other alterations, as detected by BPER NGS, in the plasma ranged from 0.6% to 23%, with a median of 2%. By comparison, in the group of patients with concordant negative results, the allelic fraction of ctDNA ranged from 0.6% to 81%, with a median of 20.3% (supplementary Table S9 , available at Annals of Oncology online). The plasma of 11 of these patients, for whom a dedicated ddPCR assay was available based on the specific KRAS codon 12 or 13 identified in the tumor, was tested. The corresponding mutation was found in 3 of the 11 tested samples (27%). The mutated allelic frequency (MAF) of these three samples were 3.3%, 3.4% and 7.2%. The number of amplifiable genomes was comparable between these three positive cases and the eight negative cases.
Discussion
By using an NGS method adapted to plasma analysis, we determined RAS mutation status in the plasma of patients with metastatic colorectal cancer. Accuracy, by comparison with RAS status in paired tumor tissue, was 85%. Accuracy was improved by multiplex digital PCR analysis of CpG island methylation in two genes (WIF1 and NPY), which was used as a second-line test for NGS-negative specimens. When positive, this test indicates the presence of the ctDNA, thus limiting the risk of NGS falsenegative results. Use of both assays increased accuracy to 95%, with inconclusive results in 20% of patients. We recently reported a similar rate of inconclusive results in an independent cohort [12] . Using highly sensitive NGS methodology without prior sample selection [5, 10] , the sensitivity of RAS mutation detection was 76% for the entire assessable population, a figure comparable to that reported elsewhere [5, 13, 14] . For example, with the IntPlex V R method, the KPLEX2 study reported a sensitivity varying from 85% to 57% according to the type of searched mutations [14] . A way to increase the sensitivity of RAS mutation detection is to restrict the analysis to patients with proven presence of ctDNA (as carried out in our study). Indeed, the use of methylation ddPCR assay significantly reduced the number of false-negative patients from 52 (13%) to 14 (4%) by identifying patients with an insufficient amount of ctDNA. After exclusion of these patients, the sensitivity of RAS mutation detection rose to 93%. In the other hand, RAS analysis could be carried out using a procedure described as showing higher sensitivity such as ddPCR targeting tumor specific mutation. When testing the plasma samples detected as negative for RAS mutation identified in the tumor, the corresponding mutation was found in 3 of the 11 plasma tested leading finally to an incompressible false negative rate around 3%. Intratumor heterogeneity is a possible explanation for these remaining discordant cases. KRAS mutations have been shown to be spatially heterogeneous in colorectal tumor [15] . An educated guess is that the tumor fragment tested for tumor RAS determination status was by chance mutated whereas the vast majority of the remaining tumor mass was negative. The ctDNA, which reflects the mean of what occur in all tumor cells, may be negative for RAS mutation detection due to the dilution of the mutated subclones in non-mutated clones.
Based solely on the plasma analysis using our pre-specified analysis (Figure 1 ), 14 patients would have received ineffective and potentially deleterious anti-EGFR therapy. All were considered as truly RAS wild-type in their plasma because of the presence of other mutations detected by NGS and/or a positive methylation assay. The plasmatic MAF was lower in these patients than in the patients with concordant negative results, showing that the lack of sensitivity was due mainly to the small amount of ctDNA. The fact that all our patients were at an early stage of the metastatic evolution of the disease (before first line chemotherapy) could explain the lower concentration of ctDNA as ctDNA concentration has been shown to be a strong prognostic marker [12] . This could explain the lower sensitivity of detection as compared with patients in latest stage of advanced disease.
On the contrary, detection of RAS mutations in plasma but not in tumor cells could exclude some patients from potentially effective anti-EGFR therapy. Initially, we found eight patients with such discordant results, which may be due as describe above to intratumor heterogeneity and/or a lack of sensitivity of the tumor mutation detection. In France, INCa-approved platforms use various RAS methodologies and are submitted to annual quality control exercises [16] . Clinical impact of truly discordant cases should be studied. In two retrospective studies, plasma RAS mutations had the same predictive value as tumor RAS mutations for anti-EGFR treatment efficacy [13, 17] . The potential efficacy of anti-EGFR antibody in patients with plasma RAS mutation but without tumor RAS mutation has to be assessed prospectively. Moreover, another important aspect is the evaluation for all patients presenting RAS mutation in ctDNA of the necessity to define a threshold of RAS detection in ctDNA. These goals were not the aim of our study, and pending such results, we think that, considering the low number of discordant cases, our results support the routine use of plasma analysis in order to obtain RAS status rapidly and thereby offer optimal first-line treatment to all patients. The presence of ctDNA in various cancer types generally correlates with the tumor stage and grade, and with the tumor burden [12, 13, 18] . In our study, in multivariate analysis, primary tumor resection and the presence of liver metastases were both significantly associated with the presence of ctDNA, but liver metastases appeared to be the key factor. When the analysis was restricted to patients with liver metastases, the accuracy of the BPER NGS and methylation tests combined reached 97%. The liver is the main metastatic site of colorectal cancer, and urgent medical treatment is critical for these often symptomatic but also potentially resectable patients. ESMO consensus guidelines currently recommend first-line anti-EGFR therapy for patients if their tumor is RAS wild-type, in order to shrink the tumor, control symptoms, and possibly permit curative-intent secondary surgery [1] .
In conclusion, even if our results are limited to the techniques used with their analytic sensitivity, we show here for the first time in a prospective study an excellent concordance between plasma and tumor RAS mutation status in metastatic colorectal cancer patients, especially those with liver metastases. These results validate the routine use of plasma RAS analysis in patients with colorectal cancer and liver metastases.
